Compare Virgin Galactic Holdings, Inc. (SPCE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Zoetis Inc — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.84 (market cap $445.69M), while Zoetis Inc trades at $74.44 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 67.8× Virgin Galactic Holdings, Inc.'s market cap, and Zoetis Inc pays a 2.9% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and Zoetis Inc for 70 Days on average.
| SPCE | ZTS | |
|---|---|---|
Market Cap | $445.69M | $30.20B |
Volume | 5,128,850 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $7.52 | $147.53 |
52-Week Low | $2.17 | $69.09 |
Typical Hold Time | 69 Days | 70 Days |
Enterprise Value | $409.68M | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.875, down 4.49% on the day, reflecting ongoing volatility amid negative profitability and cash burn. The company continues to post significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have shown smaller-than-expected EPS losses. Technical indicators are bearish, with moving averages signaling selling pressure, while RSI levels suggest potential oversold conditions. Recent news highlights a delay in commercial Delta flights to 2027 but strong ticket demand and a legal settlement resolution.
The outlook remains high-risk due to persistent cash outflows and delayed revenue growth, yet long-term potential in space tourism offers speculative upside. Investment hinges on successful execution of the 2027 cash flow target and commercial flight timeline, but shareholder dilution and high short interest pose substantial risks. Analyst consensus is mixed, with 29% buy ratings reflecting cautious optimism amid fundamental challenges.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
